BCOP CERTIFICATION EXAM ULTIMATE QUESTION BANK LATEST ACTUAL EXAM
QUESTIONS AND CORRECT DETAILED ANSWERS
SECTION 1: BREAST CANCER MANAGEMENT
1. A 58-year-old postmenopausal woman with ER/PR-positive, HER2-negative invasive
ductal carcinoma of the breast (T2N1M0) is being considered for adjuvant endocrine
therapy. Which regimen provides the greatest disease-free survival benefit in this
patient population?
A. Tamoxifen 20 mg daily for 5 years
B. Anastrozole 1 mg daily for 5 years
C. Tamoxifen for 2 years followed by anastrozole for 3 years
D. Anastrozole for 2 years followed by tamoxifen for 3 years
Answer: B
Rationale: The ATAC trial demonstrated that anastrozole is superior to tamoxifen in
postmenopausal women with hormone receptor-positive early breast cancer, showing
improved disease-free survival and reduced contralateral breast cancer risk. Extended
adjuvant therapy with aromatase inhibitors provides optimal benefit.
2. A 45-year-old premenopausal woman with ER-positive, HER2-positive breast cancer
is receiving trastuzumab and pertuzumab with docetaxel. What is the recommended
duration of HER2-directed therapy in the adjuvant setting?
A. 6 months
B. 12 months
C. 18 months
D. 24 months
Answer: B
Rationale: Current guidelines recommend 12 months of adjuvant trastuzumab (with or
without pertuzumab) for HER2-positive early breast cancer based on pivotal trials showing
optimal efficacy at this duration.
,3. A patient with metastatic breast cancer receiving palbociclib and letrozole develops
grade 3 neutropenia. What is the appropriate management strategy?
A. Discontinue both drugs permanently
B. Reduce palbociclib dose to 75 mg daily
C. Continue current dose with growth factor support
D. Increase letrozole dose to compensate
Answer: B
Rationale: For grade 3 neutropenia with palbociclib, the recommended approach is dose
reduction (to 75 mg daily) without growth factor support, with dose re-escalation not
recommended after reduction.
4. Which biomarker is essential for determining eligibility for sacituzumab govitecan in
triple-negative breast cancer?
A. PD-L1 expression
B. BRCA mutation status
C. Trop-2 expression
D. PIK3CA mutation status
Answer: C
Rationale: Sacituzumab govitecan targets Trop-2, which is overexpressed in most triple-
negative breast cancers, making it an essential biomarker for treatment eligibility
regardless of other mutations.
5. A 52-year-old patient with BRCA1-mutated metastatic breast cancer has progressed
on anthracycline and taxane therapy. Which PARP inhibitor has shown the greatest
overall survival benefit in this population?
A. Olaparib
B. Niraparib
C. Talazoparib
D. Rucaparib
Answer: C
Rationale: The EMBRACA trial showed talazoparib demonstrated superior progression-free
survival compared to physician's choice chemotherapy in BRCA-mutated breast cancer,
with a favorable safety profile.
,6. What is the recommended timing for administration of trastuzumab deruxtecan
relative to chemotherapy in HER2-low metastatic breast cancer?
A. Same day after chemotherapy
B. 24 hours after chemotherapy
C. 48 hours after chemotherapy
D. Can be administered concurrently
Answer: D
Rationale: Trastuzumab deruxtecan can be administered concurrently with chemotherapy,
unlike traditional trastuzumab which requires sequential administration.
7. A patient developing interstitial lung disease while on trastuzumab deruxtecan
requires what immediate intervention?
A. Continue treatment with steroids
B. Permanently discontinue treatment
C. Reduce dose and monitor
D. Switch to trastuzumab emtansine
Answer: B
Rationale: Any grade of ILD requires permanent discontinuation of trastuzumab
deruxtecan, as re-exposure can lead to fatal pulmonary toxicity.
8. For hormone receptor-positive, HER2-negative metastatic breast cancer with
PIK3CA mutation, which combination therapy is recommended after progression on
endocrine therapy?
A. Fulvestrant alone
B. Alpelisib plus fulvestrant
C. Everolimus plus exemestane
D. Palbociclib plus letrozole
Answer: B
Rationale: The SOLAR-1 trial demonstrated that alpelisib plus fulvestrant significantly
improved progression-free survival compared to fulvestrant alone in patients with PIK3CA-
mutated breast cancer.
, 9. What is the preferred antiemetic regimen for highly emetogenic chemotherapy in
breast cancer patients receiving anthracycline-based regimens?
A. Aprepitant, ondansetron, dexamethasone
B. Metoclopramide, diphenhydramine, dexamethasone
C. Ondansetron, dexamethasone, lorazepam
D. Granisetron, dexamethasone, haloperidol
Answer: A
Rationale: A three-drug regimen consisting of a NK1 receptor antagonist, 5-HT3
antagonist, and corticosteroid is recommended for highly emetogenic chemotherapy.
10. A patient with HER2-positive breast cancer receiving T-DM1 develops grade 2
thrombocytopenia. What is the appropriate management?
A. Hold treatment until platelet count recovers
B. Continue with dose reduction
C. Administer platelet transfusion
D. Discontinue T-DM1 permanently
Answer: B
Rationale: For grade 2 thrombocytopenia on T-DM1, dose reduction is appropriate with
resumption when platelet count recovers to grade 0-1.
11. Which genetic testing panel is most appropriate for a 35-year-old woman with
triple-negative breast cancer and a family history of ovarian cancer?
A. BRCA1/2 only
B. Multi-gene panel including BRCA, PALB2, CHEK2, ATM
C. HER2 amplification testing
D. PIK3CA mutation testing
Answer: B
Rationale: In young patients with triple-negative breast cancer and family history,
comprehensive genetic testing including multiple breast cancer susceptibility genes is
recommended.
12. What is the recommended duration of adjuvant endocrine therapy for a
premenopausal woman with high-risk hormone receptor-positive breast cancer?
A. 5 years
QUESTIONS AND CORRECT DETAILED ANSWERS
SECTION 1: BREAST CANCER MANAGEMENT
1. A 58-year-old postmenopausal woman with ER/PR-positive, HER2-negative invasive
ductal carcinoma of the breast (T2N1M0) is being considered for adjuvant endocrine
therapy. Which regimen provides the greatest disease-free survival benefit in this
patient population?
A. Tamoxifen 20 mg daily for 5 years
B. Anastrozole 1 mg daily for 5 years
C. Tamoxifen for 2 years followed by anastrozole for 3 years
D. Anastrozole for 2 years followed by tamoxifen for 3 years
Answer: B
Rationale: The ATAC trial demonstrated that anastrozole is superior to tamoxifen in
postmenopausal women with hormone receptor-positive early breast cancer, showing
improved disease-free survival and reduced contralateral breast cancer risk. Extended
adjuvant therapy with aromatase inhibitors provides optimal benefit.
2. A 45-year-old premenopausal woman with ER-positive, HER2-positive breast cancer
is receiving trastuzumab and pertuzumab with docetaxel. What is the recommended
duration of HER2-directed therapy in the adjuvant setting?
A. 6 months
B. 12 months
C. 18 months
D. 24 months
Answer: B
Rationale: Current guidelines recommend 12 months of adjuvant trastuzumab (with or
without pertuzumab) for HER2-positive early breast cancer based on pivotal trials showing
optimal efficacy at this duration.
,3. A patient with metastatic breast cancer receiving palbociclib and letrozole develops
grade 3 neutropenia. What is the appropriate management strategy?
A. Discontinue both drugs permanently
B. Reduce palbociclib dose to 75 mg daily
C. Continue current dose with growth factor support
D. Increase letrozole dose to compensate
Answer: B
Rationale: For grade 3 neutropenia with palbociclib, the recommended approach is dose
reduction (to 75 mg daily) without growth factor support, with dose re-escalation not
recommended after reduction.
4. Which biomarker is essential for determining eligibility for sacituzumab govitecan in
triple-negative breast cancer?
A. PD-L1 expression
B. BRCA mutation status
C. Trop-2 expression
D. PIK3CA mutation status
Answer: C
Rationale: Sacituzumab govitecan targets Trop-2, which is overexpressed in most triple-
negative breast cancers, making it an essential biomarker for treatment eligibility
regardless of other mutations.
5. A 52-year-old patient with BRCA1-mutated metastatic breast cancer has progressed
on anthracycline and taxane therapy. Which PARP inhibitor has shown the greatest
overall survival benefit in this population?
A. Olaparib
B. Niraparib
C. Talazoparib
D. Rucaparib
Answer: C
Rationale: The EMBRACA trial showed talazoparib demonstrated superior progression-free
survival compared to physician's choice chemotherapy in BRCA-mutated breast cancer,
with a favorable safety profile.
,6. What is the recommended timing for administration of trastuzumab deruxtecan
relative to chemotherapy in HER2-low metastatic breast cancer?
A. Same day after chemotherapy
B. 24 hours after chemotherapy
C. 48 hours after chemotherapy
D. Can be administered concurrently
Answer: D
Rationale: Trastuzumab deruxtecan can be administered concurrently with chemotherapy,
unlike traditional trastuzumab which requires sequential administration.
7. A patient developing interstitial lung disease while on trastuzumab deruxtecan
requires what immediate intervention?
A. Continue treatment with steroids
B. Permanently discontinue treatment
C. Reduce dose and monitor
D. Switch to trastuzumab emtansine
Answer: B
Rationale: Any grade of ILD requires permanent discontinuation of trastuzumab
deruxtecan, as re-exposure can lead to fatal pulmonary toxicity.
8. For hormone receptor-positive, HER2-negative metastatic breast cancer with
PIK3CA mutation, which combination therapy is recommended after progression on
endocrine therapy?
A. Fulvestrant alone
B. Alpelisib plus fulvestrant
C. Everolimus plus exemestane
D. Palbociclib plus letrozole
Answer: B
Rationale: The SOLAR-1 trial demonstrated that alpelisib plus fulvestrant significantly
improved progression-free survival compared to fulvestrant alone in patients with PIK3CA-
mutated breast cancer.
, 9. What is the preferred antiemetic regimen for highly emetogenic chemotherapy in
breast cancer patients receiving anthracycline-based regimens?
A. Aprepitant, ondansetron, dexamethasone
B. Metoclopramide, diphenhydramine, dexamethasone
C. Ondansetron, dexamethasone, lorazepam
D. Granisetron, dexamethasone, haloperidol
Answer: A
Rationale: A three-drug regimen consisting of a NK1 receptor antagonist, 5-HT3
antagonist, and corticosteroid is recommended for highly emetogenic chemotherapy.
10. A patient with HER2-positive breast cancer receiving T-DM1 develops grade 2
thrombocytopenia. What is the appropriate management?
A. Hold treatment until platelet count recovers
B. Continue with dose reduction
C. Administer platelet transfusion
D. Discontinue T-DM1 permanently
Answer: B
Rationale: For grade 2 thrombocytopenia on T-DM1, dose reduction is appropriate with
resumption when platelet count recovers to grade 0-1.
11. Which genetic testing panel is most appropriate for a 35-year-old woman with
triple-negative breast cancer and a family history of ovarian cancer?
A. BRCA1/2 only
B. Multi-gene panel including BRCA, PALB2, CHEK2, ATM
C. HER2 amplification testing
D. PIK3CA mutation testing
Answer: B
Rationale: In young patients with triple-negative breast cancer and family history,
comprehensive genetic testing including multiple breast cancer susceptibility genes is
recommended.
12. What is the recommended duration of adjuvant endocrine therapy for a
premenopausal woman with high-risk hormone receptor-positive breast cancer?
A. 5 years
